Mohamed Elsaid on The Role of Hyperlipidemia in Thrombogenesis
Mohamed Elsaid, Veterinary Surgeon at Canadian Veterinary Hospital, shared on LinkedIn:
”Hyperlipidemia in Cushing’s Syndrome and Its Role in Thrombogenesis
Hyperlipidemia is a common but often underestimated metabolic consequence of Cushing’s syndrome, and it plays a direct role in the development of thromboembolic disease.
Pathophysiology
Chronic hypercortisolism induces dyslipidemia through multiple mechanisms:
- Increased hepatic VLDL synthesis
- Enhanced lipolysis with redistribution of free fatty acids
- Reduced activity of lipoprotein lipase
- Insulin resistance contributing to altered lipid metabolism
This typically results in:
– Marked hypertriglyceridemia
– Elevated total cholesterol
– Lipemic or grossly turbid serum samples (as seen clinically)
– Link Between Hyperlipidemia and Thrombosis
Hyperlipidemia contributes to thrombogenesis by:
- Increasing blood viscosity
- Promoting endothelial dysfunction
- Enhancing platelet activation and aggregation
- Reducing fibrinolytic activity via increased PAI-1
- Upregulating procoagulant factors (Factors VIII, IX, XI)
These effects act synergistically with cortisol-induced:
Antithrombin III suppression
Decreased protein C and S activity
The result is a profound hypercoagulable state.
Clinical Implications
Patients with Cushing’s syndrome are predisposed to:
Venous thromboembolism (VTE)
Pulmonary thromboembolism
Microthrombi affecting renal, hepatic, and pulmonary perfusion
Hyperlipidemia should therefore be viewed as a pathologic contributor, not merely a biochemical abnormality.
Clinical Take-Home Messages
– Lipemic serum in Cushing’s patients is a red flag
– Routine lipid profiling should be part of endocrine case monitoring
– Thrombotic risk assessment is essential, especially in severe or untreated cases
– Early intervention may reduce morbidity and mortality.”
Stay updated with Hemostasis Today.
-
Mar 16, 2026, 17:12Cold-Stored vs Room-Temperature Platelets in Trauma-Induced Coagulopathy – JTH
-
Mar 16, 2026, 17:10Arturo Cesaro: First Meta-Analysis on the Vascular Protective Role of Semaglutide in PAD
-
Mar 16, 2026, 17:01Jeff Sternlicht: The Most Powerful Time to Lower Cholesterol Is Before Anyone Thinks You Need It
-
Mar 16, 2026, 16:14Siobhan Calafiore: Clinical Advantages of Apixaban Over Rivaroxaban in Reducing Bleeding Risk
-
Mar 16, 2026, 16:12Nuha El Sayed: Focused Summary of the 2026 ACC/AHA Guideline on Management of Dyslipidemia in Diabetes
-
Mar 16, 2026, 16:08Deepak Sudheendra: When a Vascular Looking Skin Pattern Isn’t Vascular
-
Mar 16, 2026, 16:06Surendra Karki։ Examining Blood Type and Coronary Heart Disease Risk in Australian Donors
-
Mar 16, 2026, 15:58Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
-
Mar 16, 2026, 15:56Emmanuel J. Favaloro: Latest Publication from Sydney Centres on Heparin Therapy and Monitoring